Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466618 · ClinicalTrials.gov registry record · Phase 3
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
A Phase 3 study, sponsored by Adrian Vella.
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT04466618 is a Phase 3 study that has completed, run by Adrian Vella. The registered enrollment target is 23 participants.
The verdict
NCT04466618, a Phase 3 study, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL Exendin-9,39
- BIOLOGICAL Saline + Intralipid/Heparin
- BIOLOGICAL Exendin-9,39 + Intralipid/Heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04466618
The ClinicalTrials.gov registry entry for NCT04466618 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adrian Vella, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT04466618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04466618 about?
NCT04466618 is a clinical study titled "Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes". GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes de...
What is the current status of trial NCT04466618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2021-04-15. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04466618?
The interventions under investigation include: Saline (BIOLOGICAL), Exendin-9,39 (BIOLOGICAL), Saline + Intralipid/Heparin (BIOLOGICAL), Exendin-9,39 + Intralipid/Heparin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04466618?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.